Skip to main content
Beta Version — Features and pricing may change. Send feedback
CadNews - Comparative News Analysis
Sign in
Back to brief

Politics · October 8, 2026

FDA: Mifepristone review won't be done until March

Confidence 5%
Spin 3%
2 sources analyzed →

CadNews does not determine absolute truth or endorse political viewpoints. It compares publicly available reporting, identifies shared facts, highlights framing differences, and flags uncertainty.

Neutral Summary

The Food and Drug Administration (FDA) has announced in a court filing that it expects to complete a comprehensive safety review of the abortion pill mifepristone by March. The review, commissioned by Health Secretary Robert F. Kennedy Jr., will evaluate data from approximately 100,000 patients and compare the drug's safety to surgical abortions. The update comes amid a legal challenge in Louisiana regarding the FDA's decision to allow telehealth prescriptions of the drug, a provision that currently remains in place following a Supreme Court stay.

The Food and Drug Administration (FDA) has announced in a court filing that it expects to complete a comprehensive safety review of the abortion pill mifepristone by March. The review, commissioned by Health Secretary Robert F. Kennedy Jr., will evaluate data from approximately 100,000 patients and compare the drug's safety to surgical abortions. The update comes amid a legal challenge in Louisiana regarding the FDA's decision to allow telehealth prescriptions of the drug, a provision that currently remains in place following a Supreme Court stay.